● Introduction ● Practical aspects of immunization against RSV with nirsevimab in the 2023-24 season [ver] ● More information on this website, bibliographical references and recommended links [ver]
In a few words ● In July 2023, the Public Health Commission (Ministry of Health) approved a document with recommendations for the use of nirsevimab for the prevention of RSV infections in infants, starting in the 2023-24 season that begins in next October.
● This note presents a summary with the practical aspects of greatest interest to the professionals in charge of its application.
● It should be taken into account that the autonomous communities are in charge of implementing the RSV prevention program and that they can introduce changes and specific operational aspects, even in the target population, including or not infants under 6 months of age without risk factors for RSV.
-oOo-
Introduction
At the end of last July, the Ministry of Health published the Vaccine Report and Vaccination Registry document (approved by the Public Health Commission on July 12, 2023) entitled Recommendations for the use of nirsevimab against respiratory syncytial virus for the 2023-2024 seasonand of which its most relevant aspects were summarized on this website.
Later, on this same website, the practical and operational aspects of the implementation of the VRS prevention program this coming autumn have been explained in more detail.
Now, in this note, a 2-page summary is presented in PDF format with the aim of facilitating the monitoring and application of respiratory syncytial virus (RSV) infection prevention programs for professionals, in the context of the usual variability between the Spanish autonomous communities and cities (CC. AA.).
Practical aspects of immunization against RSV with nirsevimab in the 2023-24 season
-oOo-
More information on this website
Bibliographic references and recommended links
[volver al principio]
2023-08-17 04:38:22
#Nirsevimab #summary #practical #aspects #professionals
